Related Experiment Video
Updated: May 19, 2026

Cholesterol Efflux Assay
Published on: March 6, 2012
Caveolin as a potential drug target for cardiovascular protection
Stephanie L Sellers1, Andy E Trane, Pascal N Bernatchez
1Department of Anesthesiology, Pharmacology and Therapeutics and The James Hogg Research Centre, University of British Columbia Vancouver, BC, Canada.
Abstract:
Caveolae and caveolin are key players in a number of disease processes. Current research indicates that caveolins play a significant role in cardiovascular disease and dysfunction. The far-reaching roles of caveolins in disease and dysfunction make them particularly notable therapeutic targets. In particular, caveolin-1 (Cav-1) and caveolin-3 (Cav-3) have been identified as potential regulators of vascular dysfunction and heart disease and might even confer cardiac protection in certain settings. Such a central role in vascular health therefore makes manipulation of Cav-1/3 function or expression levels clear therapeutic targets in a variety of cardiovascular related disease states. Here, we highlight the role of Cav-1 and Cav-3 in cardiovascular health and explore the potential of Cav-1 and Cav-3 derived experimental therapeutics.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Cellular Membranes and Drug Transport
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
Coronary Artery Disease IV: Preventive Measures
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiovascular Drugs: Classification based on Therapeutic Indications
